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Abstract
Background: Genetic factors as well as environmental factors are important in the development of NAFLD and in this study
we investigated associations between polymorphisms of peroxisome proliferators-activated receptor γ coactivator 1α
polymorphism (PPARGC1A) and NAFLD.
Aims: We recruited 115 patients with biopsy-proven NAFLD, 65 with NASH and 50 with simple steatosis, and 441 healthy
control subjects and investigated 15 SNPs of PPARGC1A.
Results: SNP rs2290602 had the lowest p value in the dominant mode (p = 0.00095), and the odds ratio for NAFLD (95% CI)
was 2.73 (1.48 – 5.06). rs2290602 was significantly associated with NAFLD even when the most conservative Bonferroni's
correction was applied (p = 0.0143). The frequency of the T allele of rs2290602 was significantly higher in the NASH patients
than in the control subjects (p = 0.00093, allele frequency mode), and its frequency in the NASH patients tended to be higher
than in the simple steatosis patients (p = 0.09). The results of the real-time RT-PCR study showed that intrahepatic mRNA
expression of PPARGC1A was lower in the TT group than in the GG or GT group at SNP rs2290602 (p = 0.0454).
Conclusion: This is the first study to demonstrate a significant association between genetic variations in PPARGC1A and NAFLD.
This finding suggested that PPARGC1A polymorphism and lower expression of PPARGC1A mRNA in the liver are an important
genetic contribution to etiology of NAFLD.
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Background
Nonalcoholic fatty liver disease (NAFLD) is one of the
most common causes of chronic liver injury in many
countries in the world [1,2], and epidemiological studies
have shown that its prevalence ranges from 17% to 33%
of the general population. NAFLD represents a spectrum
of conditions that are histologically characterized by mac-
rovesicular hepatic steatosis, and the diagnosis is made in
patients who have not consumed alcohol in amounts suf-
ficient to be considered to be harmful to the liver. The his-
tological changes range over a wide spectrum, extending
from simple steatosis, which is generally non-progressive,
to nonalcoholic steatohepatitis (NASH), liver cirrhosis,
liver failure, and sometimes even hepatocellular carci-
noma [3,4].
Genetic factors as well as environmental factors are
important to the development of NAFLD [5-8], and the
gene for peroxisome proliferator-activated receptor γ coac-
tivator 1α (PPARGC1A) is a candidate gene for suscepti-
bility to NAFLD, since it is involved in insulin resistance,
mitochondrial biogenesis, and oxidative phosphoryla-
tion, which are key factors in the development of NAFLD
[9-11]. Recent evidence also implicates PPARGC1A in the
homeostatic control of systemic energy metabolism, and
PPARGC1A knockout mice have been reported to develop
hepatic steatosis due to a combination of reduced mito-
chondrial respiratory capacity and increased expression of
lipogenic genes [12]. Single nucleotide polymorphisms
(SNPs) are useful tools in the search for genetic factors
responsible for disease and are being intensively investi-
gated in various common diseases, such as obesity, diabe-
tes, and hypertension. Expression of PPARGC1A has been
reported to be associated with metabolic factors, such as
type 2 diabetes, hypertension, obesity [13-18].
In this study we investigated associations between SNPs of
PPARGC1A and NAFLD in the Japanese subjects.
Methods
Subjects
A total of 115 Japanese NAFLD patients, 65 with NASH
and 50 with simple steatosis, and 441 healthy control
subjects were recruited to participate in this study at Yoko-
hama City University Hospital. All control subjects were
confirmed to have normal liver function, not to have viral
hepatitis, and not to be alcoholics. The control subjects all
had a BMI < 25 kg/m2, normal fasting glucose (<110 mg/
dl), serum triglycerides (<150 mg/dl), and serum HDL
cholesterol (>40 mg/dl) levels, and normal systolic (<130
mmHg) and diastolic blood pressure (<85 mmHg). Liver
biopsy was performed in all 115 NAFLD patients, and the
liver biopsy tissue obtained was stained with hematoxy-
lin-eosin, reticulin stain, and Masson trichrome stain. The
histological criterion used to make the diagnosis of
NAFLD was the presence of macrovesicular fatty change in
hepatocytes with displacement of the nucleus to the edge
of the cell [19]. When more than 5% of hepatocytes were
affected by macrovesicular steatosis, the patient was diag-
nosed as having either steatosis or steatohepatitis. The cri-
teria used to make the diagnosis of steatohepatitis were
the presence of lobular inflammation and the presence of
either ballooning cells or perisinusoidal/pericellular
fibrosis in zone 3 of the hepatic acinus, in addition to stea-
tosis [20,21]. Patients with any of the following diseases
were excluded from participation in this study: infectious
hepatitis (chronic hepatitis C infection or concurrent
active hepatitis B virus), autoimmune hepatitis, primary
biliary cirrhosis (PBC), sclerosing cholangitis, hemochro-
matosis, α1-antitrypsin deficiency, Wilson's disease, drug-
induced hepatitis, and alcoholic hepatitis, and heavy alco-
hol consumers (current or past daily consumption of
more than 20 g alcohol per day). No patients had clinical
evidence of hepatic decompensation, such as hepatic
encephalopathy, ascites, variceal bleeding, or a serum bil-
lirubin level greater than twice the upper limit of normal.
Written informed consent was obtained from all subjects
before their entry into this study. The study protocol con-
formed to the ethical guidelines of the 1975 Declaration
of Helsinki and was approved by the Research Committee
of Yokohama City Hospital.
Physical and laboratory evaluation
The body weight and height of the patients were measured
with a calibrated scale after requesting them to remove
their shoes and any heavy clothing. A venous blood sam-
ple was obtained from the patients after an overnight fast
(12 hours) to measure their serum AST, ALT, glucose,
immunoreactive insulin (IRI), hemoglobin A1c (HbA1c),
total cholesterol, HDL cholesterol, and triglyceride levels.
All laboratory biochemical parameters were measured
with a conventional automated analyzer. Visceral fat area
(VFA) and subcutaneous fat area (SFA) were measured by
computed tomography (CT).
DNA preparation and SNP genotyping
Genomic DNA was prepared from each blood sample by
using a commercial genomic DNA extraction kit (TALENT
s.r.l., Trieste, Italy). The PPARGC1A SNPs were selected
from the IMS-JST (Institute of Medical Science-Japan Sci-
ence and Technology Agency) SNP database [22]. We
selected the 15 SNPs with a minor allele frequency greater
than 0.2 and whose expected allele frequencies did not
widely diverge from Hardy-Weinberg equilibrium (p  >
0.001). Invader probes (Third Wave Technologies, Madi-
son, WI) were synthesized for these SNPs, and the SNPs
were genotyped in the cases and controls by a combina-
tion of multiplex PCR and the Invader assay, as described
previously [23].BMC Gastroenterology 2008, 8:27 http://www.biomedcentral.com/1471-230X/8/27
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Real-time RT-PCR for measurement of PPARGCA1 mRNA 
expression
Total RNA was isolated from samples of liver biopsy spec-
imens by using an RNeasy Mini Kit (Quiagen, Hilden,
Germany) according to the manufacturer's instructions.
The protocol included a DNase treatment step to remove
genomic DNA. The RNA was assessed quantitatively by
measuring relative absorbance at 260 nm and 280 nm,
and qualitatively by ethidium bromide agarose-gel elec-
trophoresis. Reverse transcription to produce cDNA was
performed by using a TaqMan Reverse Transcription Rea-
gents (Applied Biosystems, Foster City, CA, USA), accord-
ing to the manufacturer's instructions. The reaction
mixtures (100 μl) contained 2.5 μg of total RNA, and after
allowing the reaction to proceed for 50 minutes at 48°C,
the reverse transcriptase was inactivated by heating the
samples to 95°C for 5 minutes.
Real-time quantitative RT-PCR was performed in triplicate
by using an ABI Prism 7700 sequence detection system
(Applied Biosystems, Foster City, CA, USA) and SYBR
Green PCR Master Mix according to the manufacturer's
protocol. The following primers were used: PPARGC1A (F,
5'-TCTGACGTGACCATGGTGTT-3'; R, 5'-CATTCCAG-
GGACTCCACACT-3'). The primers were designed with
Primer Express software (Applied Biosystems, Foster City,
CA, USA) based on the sequence data obtained from the
GenBank database. β-actin (Applied Biosystems, Foster
City, CA, USA) was used as a reference; i.e., each sample
was normalized on the basis of its β-actin content. Ther-
mal cycling was performed as follows: initial denaturation
at 95°C for 10 minutes, followed by 40 cycles of 95°C for
15seconds and 60°C for 1 minute.
Statistical analysis
For each case-control study, the frequencies of the geno-
types or the alleles were compared between cases and con-
trols in three different modes by means of the χ2 test. In
the first mode (allele frequency mode), allele frequencies
were compared between cases and controls by means of a
2 × 2 contingency table. In the second mode (recessive
mode), the frequencies of the subjects who were
homozygous for allele 1 were compared with the rest by
means of a 2 × 2 contingency table, while in the third
mode (dominant mode) the frequencies of the subjects
who had allele 1 (allele 1 homozygotes and heterozy-
gotes) were compared with the rest by means of a 2 × 2
contingency table. The odds ratio (OR) and its 95% con-
fidence interval (CI) were calculated by Woolf's method.
Conformity to the Hardy-Weinberg equilibrium was
assessed by the χ2 test [24]. Haplotype blocks were calcu-
lated using Haploview 3.2 software [25]. Physical and lab-
oratory data are reported as means ± standard deviation
(SD).
Results
Case-control association study
The characteristics of NAFLD groups and control group
are compared in Table 1. We selected the 15 SNPs of the
PPARG1A gene in the IMS-JST SNP database that had a
minor allele frequency greater than 0.2. The information
on SNP location has been added in Table 2 and Fig. 1. The
rs2290602 SNP had the lowest p value in the dominant
mode (p = 0.00095, Table 2), and rs2290602 was signifi-
cantly associated with NAFLD even when the most con-
servative Bonferroni's correction was applied (p = 0.00095
× 15 × 3 = 0.04275). The OR (95% CI) was 2.73 (1.48 –
5.06) in the dominant mode, and thus the relative risk of
developing NAFLD of the subjects with the T allele was
2.73 fold higher than among the subjects without the T
allele. All SNPs except rs2290602 were in Hardy-Wein-
berg equilibrium (p > 0.1). The departure of rs2290602
from the Hardy-Weinberg equilibrium was detected in the
NAFLD group (p = 0.02), because this SNP is associated
with NAFLD and the cases were selected for the pheno-
type. Case may be biased compared to the general popu-
Table 1: Characteristics of the NAFLD patients and control subjects.
Control NAFLD P-value
Men/Women 112/329 51/64
Age (years) 47.4 ± 15.9 49.6 ± 15.1 0.20
BMI (kg/m2) 21.2 ± 2.2 27.4 ± 5.3 <0.0001
FBS (mg/dL) 90.4 ± 7.4 117.2 ± 32.0 <0.0001
HbA1c (%) 5.1 ± 0.6 5.8 ± 1.3 <0.0001
Total Cholesterol (mg/dL) 200.9 ± 33.4 211.7 ± 36.5 0.0027
Triglycerides (mg/dL) 72.2 ± 27.6 168.9 ± 110.7 <0.0001
HDL cholesterol (mg/dL) 68.1 ± 13.9 52.9 ± 20.9 <0.0001
Systolic blood pressure (mmHg) 110.5 ± 9.9 124.1 ± 14.8 <0.0001
Diastolic blood pressure (mmHg) 69.2 ± 7.3 76.8 ± 11.3 <0.0001
AST (IU/L) 20.1 ± 6.3 44.4 ± 26.3 <0.0001
ALT (IU/L) 15.7 ± 6.5 70.4 ± 53.6 <0.0001
Data are means ± SD.BMC Gastroenterology 2008, 8:27 http://www.biomedcentral.com/1471-230X/8/27
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lation. Thus, it is not unexpected that case was not in
Hardy-Weinberg equilibrium. Linkage disequilibrium
(LD) analysis revealed the presence of two blocks in the
PPARG1A  gene. SNP rs2290602 and 11 other SNPs
(rs2290604, rs3774907, rs3774908, rs2290603,
rs2970849, rs2932968, rs3755863, rs3736265,
rs3774920, rs768695, and rs3774923) were in the same
block (Fig. 1).
Next, we divided the NAFLD group into the NASH and the
steatosis group and used rs2290602 to perform case-con-
trol association studies. Although it was not conclusive
because of the small number of data, the frequency of T
allele was significantly higher in the NASH group than in
the control group (p = 0.00093, allele frequency mode).
When the frequency of the T allele in the NASH group was
compared to its frequency in the steatosis group, its fre-
quency was found to tend to be higher than in the steato-
sis group (p = 0.09). Thus, rs2290602 was significantly
more closely associated with NASH than with simple stea-
tosis (Table 3).
To investigate whether the genotype of rs2290602 SNP
were associated with the clinical parameters, we compared
age, BMI, and the fasting plasma glucose, immunoreacrive
insulin, HbA1c, total cholesterol, triglyceride, HDL cho-
lesterol, AST, ALT, VFA, and SFA between the NAFLD
patients with different genotypes (GG vs. GT + TT, or TT
vs. GT + GG) by Student's t-test. The results showed that
serum AST and ALT values of the NAFLD patients with the
TT allele were significantly higher than those of the
NAFLD patients with the GT or GG allele at SNP
rs2290602 (Table 4). When the subjects were limited to
the NASH patients, the serum AST and ALT values were
also significantly higher in the TT genotype group than in
the GT group or GG group at SNP rs2290602 (p = 0.0177,
p = 0.0140, respectively).
mRNA expression of PPARGC1A in the liver
Expression of PPARGC1A mRNA in the liver biopsy spec-
imens of NAFLD patients was evaluated by real-time RT-
PCR. The results obtained by real-time RT-PCR in the GG
or GT group (n = 10) were compared with the results in
the TT group (n = 8) at SNP rs2290602. As shown in Fig.
2, the expression of PPARGC1A mRNA transcripts in the
liver was significantly lower in the TT group than in the
GG or GT group (p = 0.0454).
Discussion
Genetic factors are important to the development of
NAFLD, and recent advantages in SNP genotyping meth-
ods have enabled the detection of genetic the variations
Table 2: Genotype frequencies and association tests of SNPs PPARGC1A gene using NAFLD and control
Rs number Location allele1/
allele2
NAFLD Control Allele frequency mode Recessive mode Dominant mode
11 12 22 11 12 22 χ2 P-value OR a (95% CI) χ2 P-value ORa (95% CI) χ2 P-value ORa (95% CI)
rs3774902 Intron 1 +745 T/C 46 49 19 207 170 63 1.6 0.2008 0.82 
(0.61 – 1.11)
1.6 0.2010 0.76 
(0.50 – 1.16)
0.4 0.52917 0.84 
(0.48 – 1.46)
rs2970871 Intron 1 +945 A/G 31 64 19 121 212 107 1.0 0.3225 1.16 
(0.87 – 1.55)
0.0 0.9478 0.98 
(0.62 – 1.56)
3.0 0.08241 1.61 
(0.94 – 2.75)
rs2970876 Intron 1 +2908 C/T 38 55 22 109 226 102 2.8 0.0964 1.28 
(0.96 – 1.72)
3.1 0.0804 1.49 
(0.95 – 2.32)
0.9 0.33573 1.29 
(0.77 – 2.15)
rs2290604 Intron 4 +848 A/G 77 33 3 261 159 21 3.2 0.0716 1.42 
(0.97 – 2.07)
3.0 0.0815 1.48 
(0.95 – 2.29)
1.0 0.32629 1.83 
(0.54 – 6.26)
rs3774907 Intron 5 +161 T/C 75 35 3 280 138 21 0.6 0.4292 1.16 
(0.80 – 1.69)
0.3 0.6083 1.12 
(0.72 – 1.73)
1.0 0.32239 1.84 
(0.54 – 6.29)
rs3774908 Intron 5 +1089 T/C 79 33 3 261 158 21 3.6 0.0580 1.44 
(0.99 – 2.10)
3.4 0.0661 1.51 
(0.97 – 2.33)
1.0 0.30970 1.87 
(0.55 – 6.39)
rs2290603 Intron 5 +3590 A/G 75 35 4 264 154 19 1.0 0.3075 1.21 
(0.84 – 1.75)
1.1 0.2933 1.26 
(0.82 – 1.94)
0.2 0.68996 1.25 
(0.42 – 3.75)
rs2290602 Intron 7 +171 T/G 34 67 13 99 222 113 8.5 0.0036 1.55 
(1.15 – 2.08)
2.4 0.1201 1.44 
(0.91 – 2.28)
10.9 0.00095 2.73 
(1.48 – 5.06)
rs2970849 Intron 7 +8096 A/G 68 42 5 232 173 34 2.2 0.1385 1.30 
(0.92 – 1.82)
1.4 0.2287 1.29 
(0.85 – 1.96)
1.6 0.20492 1.85 
(0.71 – 4.83)
rs2932968 Intron 7 +8494 T/C 74 36 4 262 157 21 1.2 0.2809 1.22 
(0.85 – 1.76)
1.1 0.2959 1.26 
(0.82 – 1.93)
0.3 0.56233 1.38 
(0.46 – 4.10)
rs3755863 Exon 8 +707 
(T/T)
G/A 32 60 23 82 222 135 7.3 0.0070 1.49 
(1.11 – 2.00)
4.7 0.0308 1.68 
(1.05 – 2.69)
5.2 0.02301 1.78 
(1.08 – 2.93)
rs3736265 Exon 9 +42 
(M/T)
A/G 81 30 3 261 158 20 5.0 0.0259 1.55 
(1.05 – 2.29)
5.2 0.0231 1.67 
(1.07 – 2.62)
0.8 0.35922 1.77 
(0.52 – 6.05)
rs3774920 Intron 10 +1732 A/G 79 32 3 263 157 21 3.8 0.0528 1.46 
(0.99 – 2.14)
3.6 0.0587 1.53 
(0.98 – 2.37)
1.0 0.31886 1.85 
(0.54 – 6.31)
rs768695 Intron 12 +4535 T/C 69 35 9 229 184 27 1.2 0.2737 1.21 (
0.86 – 1.70)
2.9 0.0863 1.44 
(0.95 – 2.20)
0.5 0.48225 0.76 
(0.34 – 1.66)
rs3774923 Exon 13 +2485 A/G 82 30 3 263 157 20 5.0 0.0256 1.55 
(1.05 – 2.29)
5.2 0.0232 1.67 
(1.07 – 2.61)
0.9 0.35349 1.78 
(0.52 – 6.09)
a OR; odds ratio,BMC Gastroenterology 2008, 8:27 http://www.biomedcentral.com/1471-230X/8/27
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associated with increased susceptibility to NAFLD. There
have been a few reports of genetic variations that are asso-
ciated with NAFLD, and they have been in the genes for
TNF receptor 2 (TNFR-2), TNF-α, micorosomal triglycer-
ide transfer protein (MTP), and methylenetetrahydro-
folate reductase (MTHFR) genes [6,7,26]. All of these
LD mapping around the PPARGC1A gene Figure 1
LD mapping around the PPARGC1A gene. LD coefficients (d) were calculated for every pair of PPARGC1A SNPs. LD 
coefficients (D') were calculated for every pair of SNPs and are shown as the strand of the LD blocks. The minor allele fre-
quencies of all SNPs used in this analysis were >20%. Each SNP is labeled with its rs number.
PPARGCA1
5’ 3’
Table 3: Results of testing for differences in SNP rs2290602 frequency between NAFLD group and control group, NASH group and 
contol group, NASH group and simple steatosis group.
NAFLD Control Allele frequency mode Recessive mode Dominant mode
S t u d y 1 11 22 21 1 1 2 2 2 χ2 P-value Odds ratio 
(95% CI)
χ2 P-value Odds ratio 
(95% CI)
χ2 P-value Odds ratio 
(95% CI)
NAFLD vs. 
Control
34 67 13 99 222 113 1.6 0.00363 1.55 
(1.15 – 2.08)
2.4 0.12008 1.44 
(0.91 – 2.28)
10.9 0.00095 2.73 
(1.48 – 5.06)
NASH vs. Control 24 34 6 99 222 113 1.0 0.00093 1.90 
(1.29 – 2.79)
6.5 0.01097 2.03 
(1.17 – 3.53)
8.5 0.00352 3.40 
(1.43 – 8.10)
NASH vs. simple 
steatosis
24 34 6 10 33 7 2.8 0.09168 1.58 
(0.93 – 2.69)
4.1 0.04270 2.40 
(1.02 – 5.66)
0.6 0.44076 1.57 
(0.49 – 5.02)BMC Gastroenterology 2008, 8:27 http://www.biomedcentral.com/1471-230X/8/27
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genes are related to inflammation, lipid metabolism, and
oxidation. We examined the 15 SNPs in PPARGC1A and
found that rs2290602 was significantly associated with
NAFLD, especially with NASH, and the frequency of the T
allele of rs2290602 was significantly higher in the NASH
patients than in the control subjects. We also found that
intrahepatic  PPARGC1A  mRNA expression was signifi-
cantly lower in the TT group than in the GG or GT group
at SNP rs2290602.
PPARGC1A interacts with peroxisome proliferators-acti-
vated receptors (PPARs) and has various functions,
including as integrator of the molecular regulatory cir-
cuitry involved in the transcriptional control of cellular
energy metabolism, including mitochondrial function
and biogenesis [27,28], and regulation of gene expression
involved in lipid and glucose metabolism. The
PPARGC1A Gly482Ser polymorphism is also associated
with obesity, hypertension, and diabetes [14-18,29].
NAFLD is often accompanied by obesity, hypertriglyceri-
demia, type 2 diabetes, and insulin resistance [30], and
PPARGC1A knockout mice develop hepatic steatosis [12].
Thus, variations in rs2290602 in the PPARGC1A  gene
would be expected to affect lipid and glucose metabolism,
and result in the development of NAFLD and NASH.
Recent evidence also implicates PPARGC1A in the home-
ostatic control of systemic energy metabolism, and
PPARGC1A  has been shown to regulate several key
hepatic gluconeogenic genes [31-34]. Recent studies have
also shown altered expression of PPARGC1A and down-
stream mitochondrial target pathways in the skeletal mus-
cle of humans with insulin resistance and diabetes [35-
37].
This study had a limitation in regard to the control sub-
jects. The number of the patients was too small for a pol-
ymorphism study. Although none of the control subjects
had abnormal liver function or was obese, we cannot
completely rule out the possibility that the control group
included patients with mild steatosis, since we did not
perform liver biopsies in the control subjects.
Conclusion
In conclusion, this is the first study to demonstrate a sig-
nificant association between genetic variations in
PPARGC1A  and NAFLD. This finding suggested that
PPARGC1A  polymorphism and lower expression of
The expression of mRNA for PPARGC1A in the liver Figure 2
The expression of mRNA for PPARGC1A in the liver. 
Significant difference in intrahepatic mRNA expression of 
PPARGC1A between the TT group (n = 8) and the GG or GT 
group (n = 10) at SNP rs2290602 (p = 0.0454).
TT GT + GG
p = 0.0454
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Table 4: Comparison between various quantitative phenotypes in groups of NAFLD patients with different SNP genotypes at 
rs2290602
GG GT+TT p value GG+GT TT p value
N 14 101 80 35
Age (years) 48.5 + 18.5 49.5 + 14.7 0.8303 48.4 + 14.4 51.7 + 16.4 0.2913
BMI (kg/m2) 27.3 + 7.2 27.2 + 4.8 0.9194 27.0 + 5.1 27.6 + 4.9 0.5581
FBS (mg/dl) 118.5 + 26.3 117.3 + 32.9 0.8929 116.8 + 32.0 118.7 + 32.8 0.7791
IRI (ul/ml) 13.6 + 6.2 13.7 + 8.9 0.9778 12.9 + 6.9 15.4 + 11.6 0.1865
HbA1c (%) 5.39 + 1.26 5.88 + 1.26 0.1890 5.83 + 1.28 5.80 + 1.23 0.9138
Total cholesterol (mg/dl) 219.1 + 35.7 213.1 + 39.3 0.6017 214.7 + 39.5 211.6 + 37.5 0.6978
HDL cholesterol (mg/dl) 50.6 + 10.0 53.3 + 22.0 0.6709 51.2 + 16.2 57.0 + 29.1 0.1800
Triglycerides (mg/dl) 144.9 + 53.7 172.1 + 116.4 0.4102 159.1 + 70.4 192.2 + 172.3 0.1469
AST (U/ml) 35.0 + 12.2 45.8 + 27.5 0.1660 40.4 + 21.3 54.5 + 34.1 0.0085
ALT (U/ml) 50.4 + 27.2 73.4 + 55.7 0.1462 62.7 + 37.7 89.9 + 76.9 0.0127
VFA (cm2) 129.3 + 32.9 135.8 + 50.0 0.7585 135.4 + 47.4 134.9 + 51.3 0.9703
SFA (cm2) 274.6 + 148.9 229.4 + 116.8 0.3821 235.4 + 123.8 230.4 + 114.2 0.8709
Data are shown as means ± SD. VFA: visceral fat area, SFA: subcutaneous fat area, AST: aspartate aminotransferase, ALT: alanine aminotransferase, 
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PPARGC1A mRNA in the liver are an important genetic
contribution to the etiology of NAFLD.
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